GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance© Stocktwits GSK's Sentiment Meter and Message Volume as of 8:30 a.m. ET on July 14, 2025 ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

GSK has previously said it was committed to supplying up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028 ...

As part of a multi-year collaboration, GSK and India’s Bharat Biotech are redoubling their efforts to bring the world’s first malaria vaccine to more countries in need at affordable prices.

GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech.

GSK announced its intention to open the Rockville vaccine R&D center back in 2015. The company first acquired the Shady Grove Drive space in 2012 after buying Human Genome Sciences.